The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 31, 2017
Filed:
Dec. 11, 2009
Somnuek Sungkanuparph, Bangkok, TH;
Sasisopin Kiertiburanakul, Bangkok, TH;
Thanyachai Sura, Bangkok, TH;
Wasun Chantratita, Bangkok, TH;
Soranun Chantarangsu, Bangkok, TH;
Angkana Charoenyingwattana, Bangkok, TH;
Surakameth Mahasirimongkol, Nonthaburi, TH;
Michiaki Kubo, Yokohama, JP;
Taisei Mushiroda, Yokohama, JP;
Yusuke Nakamura, Yokohama, JP;
Somnuek Sungkanuparph, Bangkok, TH;
Sasisopin Kiertiburanakul, Bangkok, TH;
Thanyachai Sura, Bangkok, TH;
Wasun Chantratita, Bangkok, TH;
Soranun Chantarangsu, Bangkok, TH;
Angkana Charoenyingwattana, Bangkok, TH;
Surakameth Mahasirimongkol, Nonthaburi, TH;
Michiaki Kubo, Yokohama, JP;
Taisei Mushiroda, Yokohama, JP;
Yusuke Nakamura, Yokohama, JP;
MAHIDOL UNIVERSITY, Salaya, Nakhon, TH;
RIKEN, Saitama, JP;
DEPARTMENT OF MEDICAL SCIENCES, MINISTRY OF PUBLIC, Nonthaburi, TH;
THAILAND CENTER OF EXCELLENCE FOR LIFE SCIENCES (OKMD), Bangkok, TH;
Abstract
The present invention provides a method of predicting the risk of a patient for developing cutaneous adverse drug reaction to non-nucleoside reverse transcriptase inhibitors such as nevirapine by using HLA-B*3505 allele and/or polymorphisms in the CCHCR1 gene.